Karen Ling
CIK 1597450 · EVP and Chief HR Officer · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.42M
Companies
8
Total Filings
54
Lifetime Open-Market Net
$96.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRTC | Director | 11,141 | $127.84 | $1.42M | $0 | 7 | 2026-05-29 |
| BLCO | Director | 61,518 | $16.78 | $1.03M | $71.0K | 5 | 2026-05-28 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 49,399 | $0.34 | $16.8K | $0 | 4 | 2023-06-29 |
| TXMD | Director | 4,591 | $2.07 | $9.5K | $25.1K | 6 | 2022-10-03 |
| AIG | EVP and Chief HR Officer | 10,809 | $78.78 | $851.5K | $0 | 12 | 2021-04-01 |
| Allergan plc (AGN) Delisted | EVP & Chief H.R. Officer | 25,132 | — | — | $0 | 12 | 2019-04-05 |
| ACT | Chief Human Resources Officer | 22,543 | $48.96 | $1.10M | $0 | 3 | 2015-05-19 |
| Forest Laboratories, LLC (FRX) Delisted | SVP - Chief HR Officer | 0 | $12.00 | $0 | $0 | 2 | 2014-07-02 |
Recent Filings · Page 4 of 6
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-13 | AIG | Grant (A) | — | $0 | EDGAR |
| 2019-12-30 | AIG | Grant (A) | — | $0 | EDGAR |
| 2019-12-03 | AIG | Mixed | +6,233 | -$366.4K | EDGAR |
| 2019-10-01 | AIG | Grant (A) | — | $0 | EDGAR |
| 2019-07-30 | AIG | Grant (A) | — | $0 | EDGAR |
| 2019-04-05 | Allergan plc (AGN) Delisted | Tax (F) | −394 | -$57.4K | EDGAR |
| 2019-01-03 | Allergan plc (AGN) Delisted | Tax (F) | −1,240 | -$165.7K | EDGAR |
| 2018-07-25 | Allergan plc (AGN) Delisted | Tax (F) | −715 | -$123.1K | EDGAR |
| 2018-04-05 | Allergan plc (AGN) Delisted | Tax (F) | −392 | -$64.6K | EDGAR |
| 2018-01-02 | Allergan plc (AGN) Delisted | Tax (F) | −1,152 | -$188.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.